ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: infliximab

Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis

Reuters Staff  |  

NEW YORK (Reuters Health)—About two-thirds of patients with ulcerative colitis (UC) had mucosal healing by the end of induction treatment with the infliximab biosimilar CT-P13, according to results of the first prospective study to evaluate this. CT-P13 is the first biosimilar monoclonal antibody of reference infliximab (Remicade) approved in Europe and several other countries where…

FDA Update: Infliximab Biosimilar Garners Support & Fibromyalgia Drug Receives Fast Track

  |  

Recently, an FDA committee announced support for the approval of CT-P13, an infliximab biosimilar. The FDA has also fast tracked the development of a fibromyalgia treatment designed for multiple symptoms…

Studies Challenge Conventional Infliximab Protocols in IBD

Laura Newman  |  

NEW YORK (Reuters Health)—Dose optimization of infliximab is needed much earlier in ulcerative colitis than in Crohn’s disease, a single-center retrospective study reveals. “We compared the rates of dose increases over a fairly lengthy period of time,” said Dr. Mark Silverberg, the study’s senior author from the Mount Sinai Hospital in Toronto. “Patients with ulcerative…